N. H. Hanna

发表

RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non–Small-Cell Lung Cancer

N. Hanna, N. H. Hanna, 2008 .

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

N. Hanna, N. H. Hanna, 2008 .

Respiratory Symptoms, Pulmonary Function, and Markers of Inflammation Among Bar Workers Before and After a Legislative Ban on Smoking in Public Places

N. Hanna, N. H. Hanna, 2008 .

EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib

N. Hanna, N. H. Hanna, 2006 .

Randomized Trial of Amifostine in Locally Advanced Non-Small-Cell Lung Cancer Patients Receiving Chemotherapy and Hyperfractionated Radiation: Radiation Therapy Oncology Group Trial 98-01

N. Hanna, N. H. Hanna, 2006 .

Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

N. Hanna, N. H. Hanna, 2008 .

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

N. H. Hanna, 2006 .

Vinorelbine Plus Cisplatin vs Observation in Resected Non–Small-Cell Lung Cancer

N. Hanna, N. H. Hanna, 2006 .

Computed Tomography Screening and Lung Cancer Outcomes

C. Begg, S. Swensen, J. Jett, 2008 .